• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

F4G Next Steps













They will lay off 25% of the people. Losing at least 1 DGM, 5-6 RD’s and 40-50 TBM’s. Plus cross function partner cuts. Hopefully the 10% vacancy rate reduces additional cuts.

Revenues shrinking, CV clearly stated legacy products are over promoted. Significant changes will be made. The argument that MS is paying the bills doesn’t mean it won’t be heavily impacted. Last Q saw a 15% decline in Ms revenue.

Just my opinion/guess.
 








They will lay off 25% of the people. Losing at least 1 DGM, 5-6 RD’s and 40-50 TBM’s. Plus cross function partner cuts. Hopefully the 10% vacancy rate reduces additional cuts.

Revenues shrinking, CV clearly stated legacy products are over promoted. Significant changes will be made. The argument that MS is paying the bills doesn’t mean it won’t be heavily impacted. Last Q saw a 15% decline in Ms revenue.

Just my opinion/guess.

You're thinking 40-50 TBMs will be affected by this September?
 




You're thinking 40-50 TBMs will be affected by this September?
Look at the roster on Power BI. Count vacancies. I’m guessing we’ll see another 10-20 TBM’s AA said resources will be allocated to growth areas. Since growth is non existing, I assume she’s referring to volume. So low volume Territories will go to 1 TBM.
It’s a shame to Regions w/ 5-7 TBMs. How is that a sound business decision?

One final thing, check out the KAM column. There’s around 15-16 KAM’s and 4 directors. Not good



All opinions no inside info., probably way off.